Group 1 - The SANOVO Phase III study has completed patient enrollment for the combination therapy of savolitinib (ORPATHYS) and osimertinib (TAGRISSO) in treating specific non-small cell lung cancer patients with EGFR mutations and MET overexpression [1] - The study is a randomized, controlled trial assessing the efficacy and safety of the combination therapy compared to osimertinib monotherapy, which is the current standard treatment for these patients [1] - The primary endpoint of the study is progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety [1] Group 2 - Topline results from the SANOVO study are expected to be announced in the second half of 2026, followed by submission of results to appropriate academic conferences [2] - If the results are favorable, the company plans to submit a new indication application to the National Medical Products Administration of China [2] - Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor developed jointly by AstraZeneca and the company, while osimertinib is an irreversible third-generation EGFR TKI [2]
和黄医药(00013)完成沃瑞沙®和泰瑞沙®联合疗法用于一线治疗特定肺癌患者的SANOVO中国III期研究患者入组